3-methoxynaphthalene-1-carbaldehyde | 856204-26-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-methoxynaphthalene-1-carbaldehyde
• 英文别名: 3-methoxy-1-naphthaldehyde
• CAS: 856204-26-7
• 化学式: C₁₂H₁₀O₂
• 分子量: 186.21
• InChiKey: LAKCSRAJVSQBIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methoxynaphthalene-1-carbaldehyde 在 吡啶 、 potassium permanganate 、 正丁基锂 、 三溴化硼 、 potassium hydroxide 作用下， 以 乙醚 、 正庚烷 、 二氯甲烷 、 水 为溶剂， 反应 7.0h， 生成 2-(3-hydroxy-1-naphthoyl)benzoic acid
  参考文献：
  名称：

  Discovery of Novel Naphthylphenylketone and Naphthylphenylamine Derivatives as Cell Division Cycle 25B (CDC25B) Phosphatase Inhibitors: Design, Synthesis, Inhibition Mechanism, and in Vitro Efficacy against Melanoma Cell Lines

  摘要：

  CDC25 phosphatases play a critical role in the regulation of the cell cycle and thus represent attractive cancer therapeutic targets. We previously discovered the 4-(2-carboxybenzoyl)phthalic acid (NSC28620) as a new CDC25 inhibitor endowed with promising anticancer activity in breast, prostate, and leukemia cells. Herein, we report a structure-based optimization of NSC28620, leading to the identification of a series of novel naphthylphenylketone and naphthylphenylamine derivatives as CDC25B inhibitors. Compounds 7j, 7i, 6e, 7f, and 3 showed higher inhibitory activity than the initial lead, with Ki values in the low micromolar range. Kinetic analysis, intrinsic fluorescence studies, and induced fit docking simulations provided a mechanistic understanding of the activity of these derivatives. All compounds were tested in the highly aggressive human melanoma cell lines A2058 and A375. Compound 4a potently inhibited cell proliferation and colony formation, causing an increase of the G2/M phase and a reduction of the G0/G1 phase of the cell cycle in both cell lines.

  DOI：

  10.1021/acs.jmedchem.9b00632
• 作为产物：
  描述：

  硝基萘 在 三乙基硅烷 、 sodium tetrahydroborate 、 正丁基锂 、 溴 、 sodium hydride 、 溶剂黄146 、 丙酸 、 palladium dichloride 、 sodium nitrite 作用下， 以 四氢呋喃 、 乙醇 、 正庚烷 、 溶剂黄146 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 5.59h， 生成 3-methoxynaphthalene-1-carbaldehyde
  参考文献：
  名称：

  Discovery of Novel Naphthylphenylketone and Naphthylphenylamine Derivatives as Cell Division Cycle 25B (CDC25B) Phosphatase Inhibitors: Design, Synthesis, Inhibition Mechanism, and in Vitro Efficacy against Melanoma Cell Lines

  摘要：

  CDC25 phosphatases play a critical role in the regulation of the cell cycle and thus represent attractive cancer therapeutic targets. We previously discovered the 4-(2-carboxybenzoyl)phthalic acid (NSC28620) as a new CDC25 inhibitor endowed with promising anticancer activity in breast, prostate, and leukemia cells. Herein, we report a structure-based optimization of NSC28620, leading to the identification of a series of novel naphthylphenylketone and naphthylphenylamine derivatives as CDC25B inhibitors. Compounds 7j, 7i, 6e, 7f, and 3 showed higher inhibitory activity than the initial lead, with Ki values in the low micromolar range. Kinetic analysis, intrinsic fluorescence studies, and induced fit docking simulations provided a mechanistic understanding of the activity of these derivatives. All compounds were tested in the highly aggressive human melanoma cell lines A2058 and A375. Compound 4a potently inhibited cell proliferation and colony formation, causing an increase of the G2/M phase and a reduction of the G0/G1 phase of the cell cycle in both cell lines.

  DOI：

  10.1021/acs.jmedchem.9b00632

文献信息

• [EN] PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIMIDINE
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2018210992A1

  公开（公告）日：2018-11-22

  The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R5b, and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

  本发明涉及式(I)的嘧啶衍生物，其中(R1)n，R3，R4a，R5b和Ar1如描述中所述，及其用于通过调节肿瘤中的免疫系统的再激活来治疗癌症的免疫应答。本发明进一步涉及新颖的苯并呋喃和苯并噻吩衍生物式(III)及其作为药物的使用，其制备方法，药用可接受的盐，以及作为药物的使用，包括含有式(I)的一个或多个化合物的药物组合物，尤其是它们作为前列腺素2受体EP2和/或EP4的调节剂的使用。
• Novel Cercosporamide Derivative
  申请人：Furukawa Akihiro

  公开号：US20090036492A1

  公开（公告）日：2009-02-05

  The present invention relates to a novel cercosporamide derivative, a pharmacologically acceptable salt thereof or an ester thereof which has an excellent hypoglycemic effect and is useful as a therapeutic and/or prophylactic agent for diabetes. A cercosporamide derivative having the general formula (I): [wherein X represents an oxygen atom or the like, R 1 represents a hydrogen atom or a C 1 -C 6 alkyl group, R 2 represents a hydrogen atom, a C 1 -C 6 alkyl group or a C 1 -C 6 halogenated alkyl group, R 3 represents a hydrogen atom or a C 1 -C 6 alkyl group, R 4 represents a C 6 -C 10 aryl group which may be substituted with one to five group(s) independently selected from Substituent Group a, or the like, n represents 1, 2 or 3, and Substituent Group a represents a halogen atom, a C 1 -C 6 alkyl group, a C 1 -C 6 halogenated alkyl group, a C 2 -C 6 alkenyl group, a C 2 -C 6 alkynyl group, a C 1 -C 6 alkoxy group, a C 1 -C 6 halogenated alkoxy group, a C 2 -C 6 alkenyloxy group, a C 2 -C 6 alkynyloxy group and the like], a pharmacologically acceptable salt thereof or an ester thereof.

  本发明涉及一种新型的环孢霉素衍生物，其具有优异的降血糖作用，可作为糖尿病治疗和/或预防制剂使用的药物学上可接受的盐或酯。 具有以下通式（I）的环孢霉素衍生物： [其中，X代表氧原子或类似物，R1代表氢原子或C1-C6烷基，R2代表氢原子、C1-C6烷基或C1-C6卤代烷基，R3代表氢原子或C1-C6烷基，R4代表C6-C10芳基，该芳基可被一个到五个独立选择的取代基a取代，n代表1、2或3，取代基a代表卤原子、C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6炔基、C1-C6烷氧基、C1-C6卤代烷氧基、C2-C6烯氧基、C2-C6炔氧基等]，其药学上可接受的盐或酯。
• Induction of Apoptosis by Matrine Derivative ZS17 in Human Hepatocellular Carcinoma BEL-7402 and HepG2 Cells through ROS-JNK-P53 Signalling Pathway Activation
  作者：Xiang Wang、Sen Zhang、Keyan Han、Lisheng Wang、Xu Liu

  DOI：10.3390/ijms232415991

  日期：——

  Hepatocellular carcinoma (HCC) is one of the most common malignancies and ranks third among cancer-related deaths worldwide. Using matrine as a lead compound, 12 matrine derivatives were designed and synthesised, and their antiproliferative activities were evaluated in four cancer cell lines. Eight of the twelve compounds showed strong antiproliferative activity, with an IC50 of <10 μM. The compound ZS17 exhibited strong antiproliferative activity in hepatocellular carcinoma cell lines with IC50 values in the range of 3.014–3.388 μM, which was much lower than that of matrine. Furthermore, we explored the role of ZS17 in inducing apoptosis in HCC cells in vitro and in vivo, as well as possible mechanisms involved. ZS17 inhibited the proliferation of BEL-7402 and HepG2 cells in time- and dose-dependent manners. In addition, we found that ZS17 significantly induced apoptosis and ROS (reactive oxygen species) production, promoted JNK phosphorylation, activated p53, and activated the caspase signalling pathway. Furthermore, the antioxidant NAC, JNK inhibitor SP600125, and Si-JNK increased cell viability, re-established cell metastasis, and inhibited ZS17-induced apoptosis. An in vivo antitumour assay demonstrated that ZS17 significantly reduced the number of migrating HepG2 cells in zebrafish embryos and suppressed the growth of HepG2 xenografts in nude mice without any obvious side effects. Our study demonstrated that the ROS-JNK-P53 pathway plays an important role in the destruction of liver tumour cells by ZS17. Thus, ZS17 may represent a promising chemotherapeutic agent for the treatment of HCC patients.

  肝细胞癌（HCC）是最常见的恶性肿瘤之一，在全球癌症相关死亡病例中排名第三。研究人员以马钱子碱为先导化合物，设计并合成了 12 种马钱子碱衍生物，并在四种癌细胞系中评估了它们的抗增殖活性。12 个化合物中有 8 个具有很强的抗增殖活性，IC50 为 10 μM。化合物 ZS17 在肝癌细胞系中表现出很强的抗增殖活性，其 IC50 值在 3.014-3.388 μM 之间，远低于马钱子碱。此外，我们还探讨了 ZS17 在体外和体内诱导 HCC 细胞凋亡的作用以及可能的机制。ZS17 对 BEL-7402 和 HepG2 细胞的增殖具有时间和剂量依赖性抑制作用。此外，我们还发现 ZS17 能显著诱导细胞凋亡和 ROS（活性氧）的产生，促进 JNK 磷酸化，激活 p53，并激活 caspase 信号通路。此外，抗氧化剂NAC、JNK抑制剂SP600125和Si-JNK可提高细胞活力，重建细胞转移，并抑制ZS17诱导的细胞凋亡。体内抗肿瘤试验表明，ZS17 能显著减少斑马鱼胚胎中迁移的 HepG2 细胞数量，抑制裸鼠体内 HepG2 异种移植的生长，且无明显副作用。我们的研究表明，ROS-JNK-P53 通路在 ZS17 破坏肝肿瘤细胞的过程中发挥了重要作用。因此，ZS17 可能是治疗 HCC 患者的一种有前途的化疗药物。
• Substituents at the naphthalene C3 position of (−)-Cercosporamide derivatives significantly affect the maximal efficacy as PPARγ partial agonists
  作者：Akihiro Furukawa、Tsuyoshi Arita、Takehiro Fukuzaki、Susumu Satoh、Makoto Mori、Takeshi Honda、Yumi Matsui、Kenji Wakabayashi、Shinko Hayashi、Kazushi Araki、Jun Ohsumi

  DOI：10.1016/j.bmcl.2011.12.066

  日期：2012.2

  Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a potential drug target for treating type 2 diabetes. The selective PPAR gamma modulators (SPPARMs), which partially activate the PPAR gamma transcriptional activity, are considered to improve the plasma glucose level with attenuated PPAR gamma related adverse effects. However, the relationships between desired pharmacological profiles and ligand specific PPAR gamma transcriptional profiles have been unclear. And there is also little knowledge of how to control ligand specific PPAR gamma transcriptional profiles. Herein, we present synthesis of novel derivatives containing substituent at naphthalene C3 position of compound 1. The novel derivatives showed various maximal efficacies as PPAR gamma partial agonist. (C) 2011 Elsevier Ltd. All rights reserved.
• NOVEL CERCOSPORAMIDE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1914229B1

  公开（公告）日：2010-06-16